LEADER 02279nas  2200577-  450 
001 996222948903316
005 20211118213022.0
011   $a2057-5858
035   $a(OCoLC)915087449
035   $a(CKB)3780000000055208
035   $a(CONSER)--2016229665
035   $a(DE-599)ZDB2835258-0
035   $a(NjHacI)993780000000055208
035   $a(EXLCZ)993780000000055208
100   $a20150729a20159999  ---            -
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMicrobial genomics
210  1$a[London] :$cSociety for General Microbiology,$d2015-
210 31$aLondon :$cMicrobiology Society
215   $a1 online resource
300   $aRefereed/Peer-reviewed
327   $aEfficacy and direct costs of chronic hepatitis C treatment with first generation NS3/4A protease inhibitors in a real life population -- Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study -- Prevalence of HCV genotypes in Poland - the EpiTer study -- Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases -- The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin -- The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantation.
517 1 $aMGen
531   $aMICROB GENOM
606   $aMicrobial genomics$vPeriodicals
606   $aGenomics
606   $aMicrobial genomics$2fast$3(OCoLC)fst01019505
606   $aGenome, Microbial
608   $aPeriodicals.$2lcgft
608   $aPeriodical.
608   $aPeriodicals.$2fast
608   $aFulltext.
608   $aInternet Resources.
608   $aPeriodicals.
615  0$aMicrobial genomics
615 12$aGenomics.
615  7$aMicrobial genomics.
615 22$aGenome, Microbial.
676   $a579.3135
712 02$aSociety for General Microbiology,
712 02$aMicrobiology Society,
801  0$bNjHacI
801  1$bNjHacI
906   $aJOURNAL
912   $a996222948903316
996   $aMicrobial genomics$92266131
997   $aUNISA